Compare Merck & Co., Inc. (MRK) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Merck & Co., Inc. trades at $135.74 (market cap $327.94B), while Consumer Discretionary Select Sector SPDR Fund trades at $118.5. The key difference: Merck & Co., Inc. pays a 2.56% dividend while Consumer Discretionary Select Sector SPDR Fund pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| MRK | XLY | |
|---|---|---|
Market Cap | $327.94B | — |
Sector | Health | — |
52-Week High | $132.93 | $124.52 |
52-Week Low | $77.60 | $105.64 |
Enterprise Value | $374.70B | — |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $135.55, up 3.91% today, with a bullish technical signal and strong institutional buying. Recent earnings beats and the acquisition of Terns Pharmaceuticals bolster its oncology pipeline. The stock shows robust revenue growth and profitability, though valuation ratios like a P/E of 106.34 are elevated. Analyst consensus is strongly bullish with a $140.58 price target.
Outlook is positive driven by strategic acquisitions and earnings momentum, but risks include high valuation sensitivity and competitive pressures. The stock offers growth potential with a stable dividend, yet investors should monitor execution on integration and patent expirations for sustained upside.
XLY trades at $117.89, down 1.13% on the day, with a bullish technical signal driven by moving averages. Analyst consensus is unanimously positive, with a 100% buy rating. Recent news highlights consumer discretionary as a potential dark horse, with spending shifting toward value and convenience. The ETF offers exposure to resilient consumer trends, though inflation and sentiment remain headwinds.
The outlook for XLY is supported by strong technical momentum and optimistic analyst coverage, but risks include inflation pressures and weak consumer confidence. Upside depends on sustained discretionary spending and broader economic stability. Investors should weigh the ETF's liquidity and sector positioning against macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
